These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog. Yamada H; Yoneyama F; Satoh K; Taira N Br J Pharmacol; 1991 Jul; 103(3):1713-8. PubMed ID: 1681975 [TBL] [Abstract][Full Text] [Related]
9. Cardiohemodynamic effects of SK&F 24260, D 600, diltiazem, dilazep, and trimetazidine in the dog. Imai Y; Himori N; Taira N Jpn Heart J; 1977 Jan; 18(1):120-31. PubMed ID: 846043 [TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of spontaneous nitric oxide releasers, FK409 and its derivatives. Fukuyama S; Hirasawa Y; Kato Y; Nishio M; Ohno M; Nishino S; Maeda K; Kato M; Kita Y J Pharmacol Exp Ther; 1997 Jul; 282(1):236-42. PubMed ID: 9223559 [TBL] [Abstract][Full Text] [Related]
11. FR144420, a novel, slow, nitric oxide-releasing agent. Kita Y; Ohkubo K; Hirasawa Y; Katayama Y; Ohno M; Nishino S; Kato M; Yoshida K Eur J Pharmacol; 1995 Mar; 275(2):125-30. PubMed ID: 7796846 [TBL] [Abstract][Full Text] [Related]
12. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409. Kita Y; Hirasawa Y; Maeda K; Nishio M; Yoshida K Eur J Pharmacol; 1994 May; 257(1-2):123-30. PubMed ID: 8082692 [TBL] [Abstract][Full Text] [Related]
13. Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats. Kita Y; Hirasawa Y; Kato Y; Ohkubo K; Ohno M; Nishino S; Kato M; Fukuyama S J Cardiovasc Pharmacol; 1997 Aug; 30(2):223-8. PubMed ID: 9269950 [TBL] [Abstract][Full Text] [Related]
14. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners. Kita Y; Hirasawa Y; Fukuyama S; Ohkubo K; Kato Y; Takamatsu H; Ohno M; Nishino S; Kato M; Seki J J Pharmacol Exp Ther; 1996 Feb; 276(2):421-5. PubMed ID: 8632305 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs. Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761 [TBL] [Abstract][Full Text] [Related]
16. [Hemodynamics mechanisms of changes in the right atrial pressure following intravenous injection of the depressor drugs]. Evlakhov VI; Poiasov IZ; Tkachenko BI Ross Fiziol Zh Im I M Sechenova; 2004 Jun; 90(6):719-27. PubMed ID: 15335162 [TBL] [Abstract][Full Text] [Related]
17. Hydroxyimine NO-donors; FK409 and derivatives. Yoshida K; Kita Y Curr Top Med Chem; 2005; 5(7):675-85. PubMed ID: 16101428 [TBL] [Abstract][Full Text] [Related]
18. Nitric oxide donor FK409 and 8-bromoguanosine-cyclic monophosphate attenuate cardiac contractility assessed by Emax. Hiraga H; Okubo T; Suto N; Yamamoto T; Yoshida IM; Okumura K Fundam Clin Pharmacol; 2001 Apr; 15(2):125-34. PubMed ID: 11468022 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of E4080, a novel bradycardiac agent with coronary vasodilating properties, in anesthetized dogs. Kawamura T; Adachi H; Ogawa T Eur J Pharmacol; 1991 Oct; 203(3):399-404. PubMed ID: 1773825 [TBL] [Abstract][Full Text] [Related]
20. Antianginal effects of FK409, a new spontaneous NO releaser. Kita Y; Ozaki R; Sakai S; Sugimoto T; Hirasawa Y; Ohtsuka M; Senoh H; Yoshida K; Maeda K Br J Pharmacol; 1994 Dec; 113(4):1137-40. PubMed ID: 7889266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]